GSK1904529A combined with lorlatinib produced synergistic resazurin-viability responses in four neuroblastoma cell lines, while single-agent GSK1904529A had limited effects in NB1. In a separate osteosarcoma study, 250 nM GSK1904529A did not significantly induce Saos-2 apoptosis over 24–72 h despite an active methotrexate positive control. [1,2]
Context-dependent IGF1R signaling inhibition in neuroblastoma
Cell-based study · CLB-BAR and NB1 (ALK-amplified); CLB-GAR (ALK R1275Q); CLB-GE (ALK F1174V). [1]
GSK1904529A reduced pIGF1R and pAKT in CLB-BAR, CLB-GAR and CLB-GE. ERK1/2 phosphorylation decreased mainly at higher concentrations. ALK phosphorylation and total ALK showed no obvious change. NB1 retained strong pIGF1R even at 1 µM and showed little downstream response until that concentration; the explanation remains uncertain.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 10, 25, 50, 100, 250, 500 and 1000 nM
- Exposure duration
- 2 h
- Method
- Single-agent treatment followed by immunoblotting.
- Reported limits
- The solvent for this particular experiment and the number of independent immunoblot experiments are not specified in the selected methods/caption. Uncropped blots in File S1 were not retrieved as a usable archive.
Methods and source locations
Compound reported in the paper: GSK1904529A; Compound label in the paper: GSK
Findings concern the named research compound in the reported models; salt identity, purity and Adooq lot equivalence were not established.
Results 3.3; Figure 3A–D; Methods 2.1, 2.2, 2.6
IGF1R, AKT, ERK1/2 and ALK phosphorylation: Immunoblotting; total IGF1R and ALK reprobes and tubulin loading control; 0 nM treatment comparison. — Results 3.3; Figure 3A–D; Methods 2.1, 2.2, 2.6
Lorlatinib–GSK1904529A combination response in neuroblastoma
Cell-based study · CLB-BAR, CLB-GAR, CLB-GE and NB1 neuroblastoma cells. [1]
After 72 h, combination treatment reduced resazurin viability more than the corresponding single-agent treatments. The reported combination indices were below 1 across the displayed equal-concentration pairs. GSK1904529A alone had a limited effect in CLB-BAR and NB1, particularly NB1, whereas lorlatinib alone strongly inhibited NB1. These are combination effects in cultured cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- Each drug: 10, 25, 50, 100, 250, 500 or 1000 nM in displayed equal-concentration pairs; single-agent comparators also shown.
- Exposure duration
- 72 h
- Method
- Resazurin assay, normalized to DMSO-treated controls; single-agent and paired-drug conditions.
- Vehicle
- DMSO
- Co-treatment
- Lorlatinib; equal nominal concentrations of each inhibitor.
- Reported limits
- Figure 4 caption calls panel E IC50 values, but panel E is explicitly a concentration/CI table. No IC50 values are extracted from that panel. DMSO percentage is not specified.
Methods and source locations
Compound reported in the paper: GSK1904529A; Compound label in the paper: GSK
Findings concern the named research compound in the reported models; salt identity, purity and Adooq lot equivalence were not established.
Results 3.4; Figure 4A–E (especially table E); Methods 2.3
Drug interaction at 25 nM lorlatinib + 25 nM GSK1904529A: Resazurin viability normalized to DMSO control after 72 h; CompuSyn CI analysis. CI <1 denotes synergy. Table values have no reported ± or n attached to individual CI estimates; experiments repeated at least three times. — Figure 4E, combination 2 row; Figure 4 caption; Methods 2.3
No significant apoptosis induction in Saos-2 cells under tested conditions
Cell-based study · Saos-2 human osteosarcoma cells. [2]
At 250 nM for 24, 48 or 72 h, GSK1904529A did not significantly induce apoptosis in Saos-2 cells by three assays. Methotrexate (10 µM, 48 h) served as a positive control and increased apoptosis. The finding limits any general claim that GSK1904529A necessarily kills tumor cells by apoptosis.
Literature-Reported Treatment Conditions
- Treatment concentration
- 250 nM GSK1904529A; separate positive control: 10 µM methotrexate
- Exposure duration
- GSK1904529A: 24, 48 and 72 h; methotrexate positive control: 48 h
- Method
- Single-agent GSK1904529A compared with untreated Ctrl; separate positive control.
- Reported limits
- Solvent and vehicle-matching details are not specified. The separate figure-level n = 5 and three-repeat statements are preserved without assigning a biological-replicate hierarchy.
Methods and source locations
Compound reported in the paper: GSK1904529A; Compound label in the paper: GSK1904529A (GSK)
Findings concern the named research compound in the reported models; salt identity, purity and Adooq lot equivalence were not established.
Results “GSK1904529A fails to induce OS cell apoptosis”; Figure 3A–C; Methods apoptosis assays, chemicals and statistics
Caspase-3 activity, histone-associated DNA fragmentation and TUNEL-positive nuclei: Caspase-3 activity, histone DNA ELISA and TUNEL assays; untreated Ctrl and 10 µM methotrexate positive control. Figure 3: mean ± SD, n = 5; figure experiments repeated three times. Methods TUNEL: at least 200 cells/condition in five independent experiments; replicate hierarchy is not fully defined. — Results “GSK1904529A fails to induce OS cell apoptosis”; Figure 3A–C; Methods apoptosis assays, chemicals and statistics